<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01259453</url>
  </required_header>
  <id_info>
    <org_study_id>0005011791</org_study_id>
    <secondary_id>5R01DA014502</secondary_id>
    <nct_id>NCT01259453</nct_id>
  </id_info>
  <brief_title>Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules</brief_title>
  <acronym>HVS</acronym>
  <official_title>Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DePaul University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hispanic Health Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators seek to provide immunization for individuals who are at high risk of
      contracting hepatitis B virus (HBV) infection because of their illicit drug use. The
      investigators will be using the syringe exchange programs (SEPs) in Hartford and Bridgeport,
      CT and Chicago, IL to contact high risk individuals and refer them for vaccination. The
      primary purpose of the study is to compare the standard schedule of hepatitis B vaccination
      at 0, 1, and 6 months to an accelerated schedule of vaccination at 0, 1, and 2 months. The
      investigators hypothesize that the accelerated scheduling will result in improved completion
      rates without significant loss in vaccine efficacy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2003</start_date>
  <completion_date type="Actual">August 2006</completion_date>
  <primary_completion_date type="Actual">August 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vaccine Efficacy</measure>
    <time_frame>8 months from study enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Vaccine completion rate</measure>
    <time_frame>8 months from study enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Association of exchange status with completion</measure>
    <time_frame>8 months from study enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">595</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Standard vaccination schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard dosing at 0, 1, and 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Accelerated Schedule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Accelerated dosing at 0, 1, and 2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Vaccination to prevent hepatitis B virus infection</intervention_name>
    <description>Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule</description>
    <arm_group_label>Standard vaccination schedule</arm_group_label>
    <arm_group_label>Accelerated Schedule</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrate evidence of recent injection drug use (injection stigmata),

          -  18 years of age or older,

          -  Screened for and found susceptible to HBV

          -  Able to provide informed consent.

        Exclusion Criteria:

          -  Evidence of intoxication that prevented provision of informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Heimer, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hispanic Health Council</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DePaul University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case Western Reserve Universtiy</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hu Y, Grau LE, Scott G, Seal KH, Marshall PA, Singer M, Heimer R. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med. 2008 Jul;35(1):25-32. doi: 10.1016/j.amepre.2008.03.028.</citation>
    <PMID>18541174</PMID>
  </results_reference>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2010</study_first_submitted>
  <study_first_submitted_qc>December 13, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 14, 2010</study_first_posted>
  <last_update_submitted>December 13, 2010</last_update_submitted>
  <last_update_submitted_qc>December 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>Robert Heimer</name_title>
    <organization>Yale University</organization>
  </responsible_party>
  <keyword>Hepatitis B vaccination</keyword>
  <keyword>Syringe exchange programs</keyword>
  <keyword>Injection drug users</keyword>
  <keyword>Hepatitis B prevention through vaccination</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

